Bilayer mucoadhesive buccal films with prolonged release of
ciclopirox olamine for the treatment of oral candidiasis: In
vitro development, ex vivo permeation testing, pharmacokinetic
and efficacy study in rabbits

J 2021

Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits

GAJDOŠOVÁ, Markéta, David VETCHÝ, Jan MUSELÍK, Jan GAJDZIOK, Jan JUŘICA et. al.

Basic information

Original name

Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits

Authors

GAJDOŠOVÁ, Markéta (203 Czech Republic, belonging to the institution), David VETCHÝ (203 Czech Republic, guarantor, belonging to the institution), Jan MUSELÍK (203 Czech Republic, belonging to the institution), Jan GAJDZIOK (203 Czech Republic, belonging to the institution), Jan JUŘICA (203 Czech Republic, belonging to the institution), M. VETCHÁ (203 Czech Republic), K. HAUPTMAN and V. JEKL

Edition

International Journal of Pharmaceutics, AMSTERDAM, ELSEVIER SCIENCE BV, 2021, 0378-5173

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.510

RIV identification code

RIV/00216224:14160/21:00121170

Organization unit

Faculty of Pharmacy

DOI

http://dx.doi.org/10.1016/j.ijpharm.2020.120086

UT WoS

000600740100052

Keywords in English

Mucoadhesive film; Ciclopirox olamine; Treatment of oral candidiasis; Pharmacokinetics; Rabbits; Eudragit

Abstract

V originále

The incidence of fungal infections has increased in recent decades not only in patients with predisposing and risk factors, but it has also spread up due to the widespread use of broad-spectrum antibiotics, immunosuppressants and corticosteroids. A limited number of drugs are currently used to treat oral candidiasis (OC). There is an emerging need to look for new antifungals, to rework or to explore the already known molecules. Ciclopirox olamine (CPX), a broad-spectrum antifungal agent, is currently used for topical dermatologic treatment. In this study, bilayer mucoadhesive buccal films (MBFs) containing poly(ethylene oxide) (PEO) and Eudragit (R) NM 30D (EU) with the prolonged release of ciclopirox olamine, were developed for the treatment of oral candidiasis. During ex vivo testing it was found that CPX does not pass through the porcine buccal tissue but it accumulates in it, which may be beneficial for the treatment of candidiasis in the oral cavity. In a pharmacokinetic study, the drug release from mucoadhesive films was prolonged with the maximum plasma concentration at 3.4 (1.4; 5.5) h. All rabbits with stomatitis showed progressive healing after the treatment with CPX bilayer mucoadhesive buccal films without organ pathologies.

Citovat

GAJDOŠOVÁ, Markéta, David VETCHÝ, Jan MUSELÍK, Jan GAJDZIOK, Jan JUŘICA, M. VETCHÁ, K. HAUPTMAN and V. JEKL. Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits. International Journal of Pharmaceutics. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol. 592, JAN 5 2021, p. 1-12. ISSN 0378-5173. Available from: https://dx.doi.org/10.1016/j.ijpharm.2020.120086.

@article{1745844,
   author = {Gajdošová, Markéta and Vetchý, David and Muselík, Jan and Gajdziok, Jan and Juřica, Jan and Vetchá, M. and Hauptman, K. and Jekl, V.},
   article_location = {AMSTERDAM},
   article_number = {JAN 5 2021},
   doi = {http://dx.doi.org/10.1016/j.ijpharm.2020.120086},
   keywords = {Mucoadhesive film; Ciclopirox olamine; Treatment of oral candidiasis; Pharmacokinetics; Rabbits; Eudragit},
   language = {eng},
   issn = {0378-5173},
   journal = {International Journal of Pharmaceutics},
   title = {Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits},
   url = {https://www.sciencedirect.com/science/article/pii/S0378517320310711?via%3Dihub},
   volume = {592},
   year = {2021}
}

TY  - JOUR
ID  - 1745844
AU  - Gajdošová, Markéta - Vetchý, David - Muselík, Jan - Gajdziok, Jan - Juřica, Jan - Vetchá, M. - Hauptman, K. - Jekl, V.
PY  - 2021
TI  - Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits
JF  - International Journal of Pharmaceutics
VL  - 592
IS  - JAN 5 2021
SP  - 1-12
EP  - 1-12
PB  - ELSEVIER SCIENCE BV
SN  - 03785173
KW  - Mucoadhesive film
KW  - Ciclopirox olamine
KW  - Treatment of oral candidiasis
KW  - Pharmacokinetics
KW  - Rabbits
KW  - Eudragit
UR  - https://www.sciencedirect.com/science/article/pii/S0378517320310711?via%3Dihub
N2  - The incidence of fungal infections has increased in recent decades not only in patients with predisposing and risk factors, but it has also spread up due to the widespread use of broad-spectrum antibiotics, immunosuppressants and corticosteroids. A limited number of drugs are currently used to treat oral candidiasis (OC). There is an emerging need to look for new antifungals, to rework or to explore the already known molecules. Ciclopirox olamine (CPX), a broad-spectrum antifungal agent, is currently used for topical dermatologic treatment. In this study, bilayer mucoadhesive buccal films (MBFs) containing poly(ethylene oxide) (PEO) and Eudragit (R) NM 30D (EU) with the prolonged release of ciclopirox olamine, were developed for the treatment of oral candidiasis. During ex vivo testing it was found that CPX does not pass through the porcine buccal tissue but it accumulates in it, which may be beneficial for the treatment of candidiasis in the oral cavity. In a pharmacokinetic study, the drug release from mucoadhesive films was prolonged with the maximum plasma concentration at 3.4 (1.4; 5.5) h. All rabbits with stomatitis showed progressive healing after the treatment with CPX bilayer mucoadhesive buccal films without organ pathologies.
ER  -

GAJDOŠOVÁ, Markéta, David VETCHÝ, Jan MUSELÍK, Jan GAJDZIOK, Jan JUŘICA, M. VETCHÁ, K. HAUPTMAN and V. JEKL. Bilayer mucoadhesive buccal films with prolonged release of ciclopirox olamine for the treatment of oral candidiasis: In vitro development, ex vivo permeation testing, pharmacokinetic and efficacy study in rabbits. \textit{International Journal of Pharmaceutics}. AMSTERDAM: ELSEVIER SCIENCE BV, 2021, vol.~592, JAN 5 2021, p.~1-12. ISSN~0378-5173. Available from: https://dx.doi.org/10.1016/j.ijpharm.2020.120086.

Detailed Information on Publication Record